INTRODUCTION
============

Recently, it was reported that dengue is the most common cause of fever during pregnancy (46%) in Vientiane, Laos.^[@ref1])^ In 2015, 82,000 patients in Vietnam had dengue infection with 25 deaths. The mortality rate for severe dengue fever is 0.8--2.5%, and pregnancy should be recognized as a coexisting risk factor for serious infection.^[@ref2])^ However, the maternal and fetal outcomes remain not fully understood. The first systemic review could not determine whether maternal dengue infection is a risk for adverse effects, because there were few comparative studies.^[@ref3])^ Recently, the first systematic review on outcomes of neonates born to mother with dengue fever was reported, and it demonstrated that preterm birth and low birthweight were reported to be the most common adverse pregnancy outcomes; however, dengue fever was not significantly associated with these adverse outcomes, suggesting that symptomatic dengue fever may indicate risk.^[@ref4])^ Other adverse effects such as stillbirth or postpartum hemorrhage (PPH) remain unclear. This report describes the effect of maternal dengue infection on maternal and fetal outcomes and focuses on the clinical features of patients with PPH.

MATERIALS AND METHODS
=====================

The present study was approved by the ethics committee of the Nagoya University School of Medicine (approval number: 2015--0153) and Tu Du Hospital (approval number: HNVP2016). Patients were retrospectively enrolled, including those who initially presented with fever and were diagnosed with dengue fever by blood examination and were hospitalized in Tu Du Hospital, Vietnam, from January 1, 2015 to December 31, 2015. Tu Du Hospital is a tertiary level governmental hospital and the largest maternity hospital in South Vietnam. Critical cases were referred to this hospital in Ho Chi Minh City from the provinces of South Vietnam. Demographic data, clinical and laboratory findings, and maternal and fetal outcomes were collected. Dengue virus nonstructural protein (NS) 1 antigen and dengue immunoglobulin (Ig) M/IgG antibodies were detected by SD BIOLINE Dengue Duo (Standard diagnostics, Inc., Gyeonggi-do, Republic of Korea). Primary or secondary infections were determined by dengue IgG. PPH was clinically diagnosed by attending doctors, based on vital signs and total volume of bleeding at delivery. Platelet transfusion was also decided by each attending doctor, and their decisions were based on general conditions of patients. The patients were treated at clinical manifestation with the treatment mainly consisting of fluid replacement therapy or/and blood transfusion as reported previously.^[@ref2])^ Statistical analyses were performed using the SPSS 24.0 software package (IBM Corp., Armonk, NY). Differences between the groups were considered to be statistically significant at *p* \< 0.05.

RESULTS
=======

During the study period, there were 69,562 deliveries and 20 pregnant women were diagnosed as seropositive for dengue (0.0289%). The clinical characteristics and perinatal outcomes are depicted in [Table 1](#table1){ref-type="table"}. The transfusion of platelets was required in 6 cases. There was one case of stillbirth at 39 weeks, on the third day of disease ([Supplementary Table](#tableS1){ref-type="table"}). Patients were diagnosed after 4.6 ± 2.3 days after the onset of symptoms. Cesarean section was performed in 4 cases (20.0%). One of them was performed because of a category III fetal heart rate monitoring^[@ref5])^ with Apgar scores of 7 and 8 at 1 and 5 minute, and the other 3 Cesarean section were performed because of disproportion. Additionally, 2 cases (10.5%) had a low Apgar score (\<7) at 1 minute. All live-born neonates were discharged from the hospital uneventfully. The factors related to PPH are depicted in [Table 2](#table2){ref-type="table"}. Total bleeding volume of case 1, 2 and 3 was approximately 1300, 1400, and 2000 ml, respectively ([Supplementary Table](#tableS1){ref-type="table"}). The concentrations of platelets in the maternal serum were significantly lower in these cases than those in cases without PPH (*p* = 0.001). All cases with PPH showed elevated liver enzymes, which were significantly higher than those in patients without PPH (*p* = 0.004). There were 3 patients with thrombocytopenia (≤ 50 × 10^3^ cells/μl) and without PPH, who underwent transfusion before delivery. No patient with PPH received platelet transfusion before delivery, but they required transfusion after delivery. Neither secondary infection (0/3 of PPH) nor bleeding manifestations (1/3 of PPH) were significantly associated with PPH.

###### 

The clinical characteristics and perinatal outcomes of patients

  ------------------------------------------------------------------------- -------------------
  Characteristics                                                           n = 20
  Age (years, mean ± SD)                                                    24.8 ± 3.7
  Primipara (n, %)                                                          13 (65.0)
  NS1 positive (n, %)                                                       18 (90.0)
  Secondary infection (n, %)                                                2 (10.0)
  Bleeding manifestation \* (n, %)                                          7 (35.0)
  Hematocrit (%, median, min-max)                                           39 (29.5 -- 42.5)
  Platelet (× 10^3^ cells/μl, median, min-max)                              76 (12 -- 374)
  Thrombocytopenia (\< 100,000 cells/μl, n, %)                              12 (60.0)
  Platelet transfusion (n, %)                                               6 (30.0)
  Platelet transfusion before delivery (n, %)                               3 (15.0)
  Interval between onset of symptom and diagnosis (days, mean ± SD, n=19)   4.6 ± 2.3
  Interval between onset of symptom and delivery (days, mean ± SD, n=19)    5.2 ± 2.5
                                                                            
  Perinatal outcomes                                                        n = 20
  Gestational age at delivery (weeks, mean ± SD)                            38.5 ± 1.5
  Birth weight (g, mean ± SD)                                               3021.1 ± 415.8
  Term but low birth weight (\< 2500 g, n, %)                               1 (5.0)
  Preterm delivery (\< 37 weeks, n, %)                                      4 (20.0)
  Premature rupture of the membrane (n, %)                                  8 (40.0)
  Stillbirth (n, %)                                                         1 (5.0)
  Category III fetal heart rate monitoring (n, %)                           1/19 (5.3)
  Cesarean section (n, %)                                                   4 (20.0)
  Postpartum hemorrhage (n, %)                                              3 (15.0)
  \< 7 of 1 minute Apgar score (n, %)                                       2/19 (10.5)
  \< 7 of 5 minute Apgar score (n, %)                                       0/19 (0.0)
  ------------------------------------------------------------------------- -------------------

\*Petechia or bleeding in oral cavity.

###### 

Comparison of clinical findings between no PPH and PPH patient with dengue

  ----------------------------------------------------------------------------------------------------------
  Number of Patients                                No PPH (n=17)          PPH (n=3)             *P* value
  ------------------------------------------------- ---------------------- --------------------- -----------
  Age (years, mean ± SD)\*                          25.0 ± 3.8             23.7 ± 3.5            0.58

  Gestational age at delivery\                      38.2 ± 1.8             38.6 ± 0.4            0.34
  (weeks, mean ± SD)\*\*                                                                         

  Birth weight (g, mean ± SD) \*                    2961.8 ± 423.0         3216.7 ± 354.7        0.34

  Hematocrit (%, median, min-max)                   39.0 (29.5 -- 42.5)    39.0 (30.0 -- 39.7)   0.364

  Platelet (×10^3^ cells/μl, median, min-max)\*\*   90.0 (19.0 -- 374.0)   40.0 (12.0 -- 57.0)   0.001

  Elevated liver enzyme (n, %)\*\*\*                1 (5.9)                3 (100.0)             0.004

  Interval from onset of symptom to diagnosis\      4.7 ± 2.4              4.3 ± 1.2             0.86
  (days, mean ± SD)\*\*                                                                          

  Interval from onset of symptom to delivery\       5.4 ± 2.7              4.3 ± 1.2             0.72
  (days, mean ± SD)\*\*                                                                          

  NS1 positive (n, %)\*\*\*                         16 (94.1)              2 (66.7)              0.28

  Secondary infection (n, %)                        2 (11.8)               0 (0.0)               0.72

  Bleeding manifestation (n, %)                     6 (35.2)               1 (5.9)               0.73

  Platelet transfusion before delivery (n, %)       3 (17.6)               0 (0.0)               0.60

  Platelet transfusion\*\* (n, %)                   3 (17.6)               3 (100.0)             0.018

  Premature rupture of membranes (n, %)             7 (41.2)               1 (5.9)               0.67

  Cesarean section (n, %)                           3 (17.6)               1 (5.9)               0.51
  ----------------------------------------------------------------------------------------------------------

Note: The differences were detected using \*unpaired *t* - test, \*\*Mann-Whitney *U* test, for continuous variables in accordance with normal or non-normal distribution. \*\*\*Fisher's exact test were used for categorical variables.

All cases were diagnosed during the third trimester ([Supplementary Table](#tableS1){ref-type="table"}). There was no reported maternal death.

DISCUSSION
==========

We demonstrated the perinatal outcomes of 20 pregnant women with dengue fever. The rates of preterm birth, low birth weight, and stillbirth were 20%, 5.0%, and 5.0%, respectively, which were similar to those in previous reports.^[@ref1],[@ref3],[@ref4])^ However, live-born neonates were discharged uneventfully. There were no miscarriages or congenital anomalies because all cases were diagnosed at the third trimester. The rate of PPH was 15.0% in this study, but others reported that it was approximately 10.0%,^[@ref6],[@ref7])^ and 19.0%.^[@ref8])^

As reported previously,^[@ref1],[@ref4])^ most cases of dengue fever during pregnancy had favorable outcomes for the mothers and neonates; therefore, almost of them could continue their pregnancy until late term or full term period with adequate fluid replace therapy. However, 3 cases were complicated by PPH. PPH is a life-threatening complication,^[@ref8],[@ref9])^ but appropriate management including efficient transfusion would help maternal lives.^[@ref10]-[@ref12])^ Thus, the risk factor of PPH among pregnant women complicated with dengue fever was also examined in the current study. Their platelet concentrations were significantly lower than those of patients without PPH. In addition, all cases presented with elevated liver enzymes. Low platelets and elevated liver enzymes were a part of the diagnostic criteria of HELLP syndrome, which is a severe obstetric disease.^[@ref13])^ Patients with similar clinical findings of HELLP syndrome maybe at risk of PPH although a large sample size is necessary to validate it. A previous report suggested that the presence of bleeding manifestations or clinical symptoms may be related to PPH^[@ref8])^ or adverse effects,^[@ref4])^ respectively, but this study could not confirm these findings. Secondary infections cause a severe infection,^[@ref2])^ but these were not significantly associated with PPH, which was similar to the previous report.^[@ref6])^ Low platelets and elevated liver enzymes might be predictive factors for PPH, and transfusion would be prepared for childbirth.

The limitation of this study is the small population. We could not exclude other risk factors of PPH in patients with dengue fever, although the relationship between low platelets and PPH seems reasonable.

From the findings in this study, all pregnant patients with denguefever should have their platelets evaluated. Although further investigation is required, patients with low platelets should be checked for elevated liver enzymes and managed to prevent PPH with platelets transfusion before delivery.
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SUPPLEMENTARY MATERIAL
======================

###### 

Clinical Profile of patients in this study

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient\   Age   Parity   GA      Int. 1   Int. 2   NS1   Infection   Platelet\           Hct\   AST\     ALT\     Bleeding   BT    BT-pre   PROM   MOD    Birth\       Ap1/5   PPH
  No.                                                                   (×10^3^ cells/μl)   (%)    (IU/l)   (IU/l)                                           weight (g)           
  ---------- ----- -------- ------- -------- -------- ----- ----------- ------------------- ------ -------- -------- ---------- ----- -------- ------ ------ ------------ ------- -----
  1          24    1        38w4d   5        5        N     Primary     12                  39     90       34       Pet, B     Yes   No       Yes    VD     3150         8/9     Yes

  2          20    0        38w2d   5        5        P     Primary     40                  39.7   1526     934      N          Yes   No       No     CS     3600         6/8     Yes

  3          27    3        39w0d   3        3        P     Primary     57                  30     53       11       N          Yes   No       No     VD     2900         8/9     Yes

  4          24    0        36w6d   10       7        P     Primary     19                  39     ND       ND       Pet        Yes   Yes      Yes    VD     3000         8/9     No

  5          31    1        33w6d   4        4        P     Primary     36                  37.8   ND       ND       Pet        Yes   Yes      No     VD     2250         7/8     No

  6          28    0        39w5d   3        2        P     Primary     37                  39     39       40       Pet        Yes   Yes      Yes    VD     3000         8/9     No

  7          26    1        39w6d   6        6        P     Secondary   39                  42     117      49       Pet        No    No       No     VD     3300         8/9     No

  8          33    1        40w1d   5        3        P     Primary     52                  41.1   ND       ND       N          No    No       Yes    VD     3600         8/9     No

  9          22    0        37w6d   7        6        P     Primary     68                  41.7   ND       ND       N          No    No       No     VD     3100         8/9     No

  10         22    0        37w3d   7        7        P     Secondary   72                  38.8   ND       ND       N          No    No       Yes    VD     2200         8/9     No

  11         25    0        39w1d   3        3        P     Primary     80                  39.6   39       15       N          No    No       No     VD     3100         8/9     No

  12         20    0        36w3d   10       9        P     Primary     90                  40.1   ND       ND       Pet        No    No       Yes    CS     2400         6/7     No

  13         25    0        38w2d   9        9        N     Primary     100                 41.3   ND       ND       N          No    No       Yes    CS     3100         7/8     No

  14         23    0        39w0d   5        3        P     Primary     114                 36.2   33       13       N          No    No       No     VD     3000         IUFD    No

  15         22    0        39w4d   3        3        P     Primary     120                 33.6   37       9        N          No    No       No     VD     2600         8/9     No

  16         30    1        39w0d   2        2        P     Primary     140                 29.5   19       9        N          No    No       No     VD     3600         8/9     No

  17         22    0        39w4d   2        2        P     Primary     145                 30.1   41       16       N          No    No       No     VD     2950         7/8     No

  18         28    1        38w3d   6        6        P     Primary     145                 41.6   ND       ND       Pet        No    No       No     VD     3350         8/9     No

  19         21    0        39w6d   4        3        P     Primary     184                 42.5   47       15       N          No    No       No     CS\*   3200         7/8     No

  20         23    0        34w6d   ND       ND       P     Primary     374                 32.5   ND       ND       N          No    No       Yes    VD     2600         8/9     No
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GA, gestational age at delivery; Int. 1, interval between onset of symptom and diagnosis; Int. 2, interval between onset of symptom and delivery; Hct, hematocrit; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BT, platelet transfusion; BT-pre, platelet transfusion before delivery; PROM, premature rupture of membrane; MOD, mode of delivery; Ap1/5, Apgar scores at 1/5minutes; PPH, postpartum hemorrhage; Pet, petechial; B, bleeding in oral cavity; N, negative; P, positive; VD, vaginal delivery; CS, Cesarean section; ND, not determined; IUFD, intrauterine fetal death

\*category III for fetal heart monitoring.

PPH

:   postpartum hemorrhage

NS

:   nonstructural protein

Ig

:   immunoglobulin
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